- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | AROA BIOSURGERY LIMITED: Application for quotation of securities - ARX | - | ASX | ||
| 09.04. | AROA BIOSURGERY LIMITED: Notification of cessation of securities - ARX | - | ASX | ||
| 30.03. | Aroa Biosurgery's Symphony Shows Positive Preliminary Results For Diabetic Foot Ulcers | 2 | RTTNews | ||
| AROA BIOSURGERY Aktie jetzt für 0€ handeln | |||||
| 30.03. | AROA Biosurgery Completes Randomised Controlled Trial for Symphony; Preliminary Read-Out indicates Primary Endpoint Met | 283 | PR Newswire | AUCKLAND, New Zealand, March 29, 2026 /PRNewswire/ -- Aroa Biosurgery Limited today announced completion of its randomised controlled trial (RCT) evaluating Symphony... ► Artikel lesen | |
| 29.03. | AROA BIOSURGERY LIMITED: Symphony Randomised Control Trial Complete | - | ASX | ||
| 24.03. | AROA BIOSURGERY LIMITED: Release of Shares from Voluntary Escrow | 1 | ASX | ||
| 10.03. | Vital Signs Podcast: Inside Aroa's MASTRR clinical registry | 1 | Stockhead | ||
| 03.02. | AROA BIOSURGERY LIMITED: Application for quotation of securities - ARX | - | ASX | ||
| 03.02. | AROA BIOSURGERY LIMITED: Eligible NZ Employees Issued with ARX Shares | - | ASX | ||
| 02.02. | AROA BIOSURGERY LIMITED: AROA Business Update Presentation | - | ASX | ||
| 02.02. | AROA BIOSURGERY LIMITED: AROA Business Update | - | ASX | ||
| 27.01. | AROA BIOSURGERY LIMITED: Notification of Investor Webinar | - | ASX | ||
| 22.01. | AROA BIOSURGERY LIMITED: Study Demonstrates Effectiveness & Economic Value of Myriad | 1 | ASX | ||
| 09.01. | AROA BIOSURGERY LIMITED: Notification of cessation of securities - ARX | 1 | ASX | ||
| 18.12.25 | AROA BIOSURGERY LIMITED: Symphony Outpatient Reimbursement Update | - | ASX | ||
| 17.12.25 | Multi-channel sales strategy drives growth for tissue repair biotech Aroa | 20 | Stockhead | ||
| 25.11.25 | Aroa Biosurgery Reports NZ$44.9m in Product Revenue for First Six Months of FY26 | 1 | smallcaps.com.au | ||
| 25.11.25 | Health Check: It's quarterly report 'Liberation Day' for Aroa after a bumper first half result | 1 | Stockhead | ||
| 24.11.25 | AROA BIOSURGERY LIMITED: Aroa Half Year Results Presentation | - | ASX | ||
| 24.11.25 | AROA BIOSURGERY LIMITED: Aroa Biosurgery H1 FY26 Results | - | ASX |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 84,65 | +0,42 % | BioNTech SE: BioNTechs und DualityBios Antikörper-Wirkstoff-Konjugat-Kandidat Trastuzumab Pamirtecan zeigte klinisch relevante Wirksamkeit bei Patientinnen mit rezidivierendem HER2-exprimierendem Gebärmutterkrebs | Trastuzumab Pamirtecan, ein innovativer gegen HER2 gerichteter Antikörper-Wirkstoff-Konjugat-Kandidat, erreichte den primären Wirksamkeitsendpunkt in einer Phase-2-Kohorte bei stark vorbehandelten Patientinnen... ► Artikel lesen | |
| EVOTEC | 5,545 | +2,88 % | Mutares: Exklusiv-Interview - Deutz, Elmos, Evotec, Infineon und Rheinmetall - Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| MODERNA | 45,855 | -0,26 % | Moderna - MRNA: Impfstoff-Aktie mit mega-starkem Comeback! | + 100 Prozent in 6 Monaten! mrRNA-Impfstoffe gegen Krebs, Grippe & RSV bei Moderna in der Pipeline! Neue Rallye trotz US-Gesundheitsminister Robert F. Kennedy? Moderna (MRNA) - ISIN US60770K1079 Rückblick:... ► Artikel lesen | |
| NOVAVAX | 7,370 | +0,14 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,800 | +1,45 % | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Sonstiges
Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest
09.04.2026... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,994 | -1,92 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| BIOMARIN PHARMACEUTICAL | 47,310 | +1,70 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 26.03.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 26.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 26.03.2026.ISIN NameCA2568277834 DOLLY... ► Artikel lesen | |
| IBIO | 1,822 | +2,59 % | iBio, Inc.: iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia | IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body compositionFirst participants expected to be dosed in 2Q 2026 SAN... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,960 | +4,21 % | Arbutus Biopharma Corporation: Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B | Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:... ► Artikel lesen | |
| GALAPAGOS NV | 24,560 | +2,42 % | Galapagos Enters Framework Agreement With Gilead In Connection With Ouro Deal | FOSTER CITY (dpa-AFX) - Galapagos (GLPG, GLPG.AS) has entered into a binding agreement with Gilead Sciences (GILD) in connection with Gilead's agreement to acquire all of the outstanding equity... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,040 | +3,05 % | Cellectar Biosciences, Inc.: Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) | FLORHAM PARK, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs... ► Artikel lesen | |
| CYTODYN | 0,290 | 0,00 % | CytoDyn Inc.: CytoDyn to Present at the AACR Annual Meeting 2026 |
AROA BIOSURGERY LIMITED gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AROA BIOSURGERY LIMITED finden Sie auf Wallstreet Online.